Cardiovascular Diseases : From Molecular Pharmacology to Evidence-Based Therapeutics.

By: Li, Y. Robert
Contributor(s): Li, Yunbo
Publisher: New York : John Wiley & Sons, Incorporated, 2015Copyright date: ©2015Edition: 1st edDescription: 1 online resource (504 pages)Content type: text Media type: computer Carrier type: online resourceISBN: 9781118889947Subject(s): Cardiovascular system -- Diseases -- Chemotherapy.;Cardiovascular system -- Diseases -- DiagnosisGenre/Form: Electronic books. Additional physical formats: Print version:: Cardiovascular Diseases : From Molecular Pharmacology to Evidence-Based TherapeuticsDDC classification: 616.1/061 LOC classification: RC669 -- .L5 2015ebOnline resources: Click to View
Contents:
Intro -- Title Page -- Copyright Page -- Contents -- Preface -- List of Abbreviations -- Unit I General Introduction -- Chapter 1 Introduction to Cardiovascular Diseases -- 1.1 Overview -- 1.2 Definition of Cardiovascular Diseases -- 1.3 Classification of Cardiovascular Diseases -- 1.3.1 Classification Based on Anatomical Location -- 1.3.2 Classification Based on the Involvement of Atherosclerosis -- 1.3.3 Total Cardiovascular Diseases and ICD-10 Classification -- 1.4 Prevalence, Incidence, and Trend of Cardiovascular Diseases -- 1.4.1 NCDs and Cardiovascular Diseases: The Global Status -- 1.4.2 The Status of Cardiovascular Diseases in the United States -- 1.4.3 The Status of Cardiovascular Diseases in China -- 1.5 Risk Factors of Cardiovascular Diseases -- 1.5.1 Classification of Cardiovascular Disease Risk Factors -- 1.5.2 Major Cardiovascular Disease Risk Factors and Their Impact -- 1.6 Prevention and Control of Cardiovascular Diseases -- 1.6.1 The UN High-Level Meeting and Tackling Cardiovascular Diseases at the Global Level -- 1.6.2 The World Heart Federation Call to Action to Prevent and Control Cardiovascular Diseases -- 1.6.3 The AHA 2010 Health Impact Goal, 2020 Health Impact Goal, and Ideal Cardiovascular Health -- 1.6.4 US DHSS "Million Hearts" Initiative -- 1.7 Cardiovascular Risk Prediction and Evidence-based Treatments -- 1.7.1 Cardiovascular Risk Prediction -- 1.7.2 Evidence-Based Treatments -- 1.8 Summary of Chapter Key Points -- 1.9 Self-Assessment Questions -- References -- Chapter 2 Introduction to Principles of Pharmacology -- 2.1 Overview -- 2.2 Definitions and History -- 2.2.1 What Is Pharmacology? -- 2.2.2 Definitions of Related Terms -- 2.2.3 A Brief History of Pharmacology -- 2.3 Pharmacological Paradigm: the Central Dogma in Pharmacology -- 2.3.1 Drug Names, Sources, Preparations, and Administration.
2.3.2 Pharmacokinetics -- 2.3.3 Pharmacodynamics -- 2.3.4 Drug Toxicity -- 2.3.5 Pharmacogenetics and Pharmacogenomics -- 2.4 Principles of Drug Discovery, Development, and Regulation -- 2.4.1 Definitions -- 2.4.2 The Paradigm of Drug Creation and Survival -- 2.4.3 The FDA Drug Review and Approval Process -- 2.5 Pharmacology Subspecialties -- 2.6 Introduction to Cardiovascular Pharmacology -- 2.6.1 Definition and Scope -- 2.6.2 New Developments and Challenges -- 2.6.3 Systems Pharmacology in the Management of Cardiovascular Diseases -- 2.6.4 Polypill for the Management of Cardiovascular Diseases -- 2.6.5 Protein Therapeutics of Cardiovascular Diseases -- 2.6.6 Gene Therapy of Cardiovascular Diseases -- 2.6.7 Stem Cell Therapy of Cardiovascular Diseases -- 2.7 Summary of Chapter Key Points -- 2.8 Self-Assessment Questions -- References -- Unit II Dyslipidemias -- Chapter 3 Overview of Dyslipidemias and Drug Therapy -- 3.1 Introduction -- 3.2 Lipoprotein Metabolism -- 3.2.1 Definition, Structure, and Classification of Lipoproteins -- 3.2.2 Metabolic Pathways of Lipoproteins and Drug Therapy -- 3.3 Dyslipidemias and Genetic Lipoprotein Disorders -- 3.3.1 Classification and Molecular Etiologies -- 3.3.2 The Four Types of Dyslipidemias and Their Underlying Genetic Lipoprotein Disorders -- 3.4 Mechanistically Based Drug Therapy of Dyslipidemias -- 3.5 Summary of Chapter Key Points -- 3.6 Self-Assessment Questions -- References -- Chapter 4 Drugs for Dyslipidemias -- 4.1 Overview -- 4.2 Statins -- 4.2.1 General Introduction to Drug Class -- 4.2.2 Chemistry and Pharmacokinetics -- 4.2.3 Molecular Mechanisms and Pharmacological Effects -- 4.2.4 Clinical Uses -- 4.2.5 Therapeutic Dosages -- 4.2.6 Adverse Effects and Drug Interactions -- 4.2.7 Summary of Statin Drugs -- 4.3 Bile Acid Sequestrants -- 4.3.1 General Introduction to Drug Class.
4.3.2 Chemistry and Pharmacokinetics -- 4.3.3 Molecular Mechanisms and Pharmacological Effects -- 4.3.4 Clinical Uses -- 4.3.5 Therapeutic Dosages -- 4.3.6 Adverse Effects and Drug Interactions -- 4.3.7 Summary of Bile Acid Sequestrants -- 4.4 Cholesterol Absorption Inhibitors -- 4.4.1 General Introduction to Drug Class -- 4.4.2 Chemistry and Pharmacokinetics -- 4.4.3 Molecular Mechanisms and Pharmacological Effects -- 4.4.4 Clinical Uses -- 4.4.5 Therapeutic Dosages -- 4.4.6 Adverse Effects and Drug Interactions -- 4.4.7 Summary of Ezetimibe -- 4.5 Fibrates -- 4.5.1 General Introduction to Drug Class -- 4.5.2 Chemistry and Pharmacokinetics -- 4.5.3 Molecular Mechanisms and Pharmacological Effects -- 4.5.4 Clinical Uses -- 4.5.5 Therapeutic Dosages -- 4.5.6 Adverse Effects and Drug Interactions -- 4.5.7 Summary of Fibrates -- 4.6 Niacin -- 4.6.1 General Introduction to Niacin -- 4.6.2 Chemistry and Pharmacokinetics -- 4.6.3 Molecular Mechanisms and Pharmacological Effects -- 4.6.4 Clinical Uses -- 4.6.5 Therapeutic Dosages -- 4.6.6 Adverse Effects and Drug Interactions -- 4.6.7 Summary of Niacin -- 4.7 New Drugs for HoFH -- 4.7.1 Lomitapide -- 4.7.2 Mipomersen -- 4.7.3 Summary of New Drugs for HoFH -- 4.8 Phytosterols and Phytostanols -- 4.8.1 Introduction to Phytosterols and Phytostanols -- 4.8.2 Molecular Mechanisms and Pharmacological Effects -- 4.8.3 Clinical Uses -- 4.8.4 Therapeutic Dosages -- 4.8.5 Adverse Effects and Drug Interactions -- 4.8.6 Summary of Phytosterols/Phytostanols -- 4.9 Omega-3 Fatty Acids -- 4.9.1 Introduction to Omega-3 Fatty Acids -- 4.9.2 Molecular Mechanisms and Pharmacological Effects -- 4.9.3 Clinical Uses -- 4.9.4 Therapeutic Dosages -- 4.9.5 Adverse Effects and Drug Interactions -- 4.9.6 Summary of Omega-3 Fatty Acids -- 4.10 Emerging Therapeutic Modalities for Dyslipidemias.
4.10.1 Emerging Therapeutic Strategies Targeting LDL -- 4.10.2 Novel Therapeutic Strategies Targeting HDL -- 4.10.3 Summary of Emerging Drugs -- 4.11 Summary of Chapter Key Points -- 4.12 Self-Assessment Questions -- References -- Chapter 5 Management of Dyslipidemias: Principles and Guidelines -- 5.1 Overview -- 5.2 General Principles of the Management of Dyslipidemias -- 5.2.1 Defining Dyslipidemias in the Context of Disease Management -- 5.2.2 Understanding Laboratory Lipid Profiles -- 5.2.3 Cardiovascular Risk Assessment -- 5.2.4 Treatment Goals -- 5.2.5 General Approaches to Management: Lifestyle Modifications and Drug Therapies -- 5.2.6 Management in Specific Clinical Settings -- 5.2.7 Treatment Monitoring and Adherence -- 5.3 Current Evidence-Based Guidelines on the Management of Dyslipidemias -- 5.3.1 Defining Clinical Guidelines in the Context of Dyslipidemia Management -- 5.3.2 Classification of Evidence-Based Guideline Recommendations and Strength of Evidence -- 5.3.3 Current Guidelines on the Management of Dyslipidemias -- 5.3.4 Comparison and Contrast of Current Lipid Guidelines -- 5.4 Summary of Chapter Key Points -- 5.5 Self-Assessment Questions -- References -- Unit III Hypertension and Multitasking Cardiovascular Drugs -- Chapter 6 Overview of Hypertension and Drug Therapy -- 6.1 Introduction -- 6.2 Definitions, Classifications, and Epidemiology of Hypertension -- 6.2.1 Definitions and Classifications -- 6.2.2 Epidemiology and Health Impact of Hypertension -- 6.3 Pathophysiology of Hypertension -- 6.3.1 Physiology of Blood Pressure Regulation -- 6.3.2 Molecular Pathophysiology of Hypertension Development -- 6.4 Mechanistically Based Drug Therapy of Hypertension: An Overview -- 6.4.1 Historical Overview -- 6.4.2 Mechanistic Overview -- 6.5 Summary of Chapter Key Points -- 6.6 Self-Assessment Questions -- References.
Chapter 7 Diuretics -- 7.1 Overview -- 7.2 Volume Regulation and Drug Targeting -- 7.2.1 Renal Physiology and Volume Regulation -- 7.2.2 Drug Class and Drug Targeting -- 7.3 Thiazide and Thiazide-Type Diuretics -- 7.3.1 General Introduction to Drug Class -- 7.3.2 Chemistry and Pharmacokinetics -- 7.3.3 Molecular Mechanisms and Pharmacological Effects -- 7.3.4 Clinical Uses -- 7.3.5 Therapeutic Dosages in Cardiovascular Applications -- 7.3.6 Adverse Effects and Drug Interactions -- 7.3.7 Summary of Thiazide and Thiazide-Type Diuretics -- 7.4 Loop Diuretics -- 7.4.1 General Introduction to Drug Class -- 7.4.2 Chemistry and Pharmacokinetics -- 7.4.3 Molecular Mechanisms and Pharmacological Effects -- 7.4.4 Clinical Uses -- 7.4.5 Therapeutic Dosages in Heart Failure Treatment -- 7.4.6 Adverse Effects and Drug Interactions -- 7.4.7 Summary of Loop Diuretics -- 7.5 Potassium-Sparing Diuretics -- 7.5.1 General Introduction to Drug Class -- 7.5.2 Chemistry and Pharmacokinetics -- 7.5.3 Molecular Mechanisms and Pharmacological Effects -- 7.5.4 Clinical Uses -- 7.5.5 Therapeutic Dosages -- 7.5.6 Adverse Effects and Drug Interactions -- 7.6 Other Diuretics -- 7.7 Summary of Chapter Key Points -- 7.8 Self-Assessment Questions -- References -- Chapter 8 Sympatholytics -- 8.1 Overview -- 8.2 Sympathetic Nervous System and Drug Targeting -- 8.2.1 Basic Divisions of the Nervous System -- 8.2.2 Sympathetic Nervous System and Cardiovascular Diseases -- 8.2.3 Drug Class and Drug Targeting -- 8.3 α-Adrenergic Receptor Antagonists -- 8.4 β-Adrenergic Receptor Antagonists -- 8.4.1 General Introduction to Drug Class -- 8.4.2 Chemistry and Pharmacokinetics -- 8.4.3 Molecular Mechanisms and Pharmacological Effects -- 8.4.4 Clinical Uses -- 8.4.5 Dosage Forms and Strengths -- 8.4.6 Adverse Effects and Drug Interactions -- 8.5 Centrally Acting Sympatholytics.
8.6 Summary of Chapter Key Points.
Summary: Written in an accessible style and consistent format, the book covers both the fundamentals and advances in the pharmacology of cardiovascular drugs, as well as their integrated applications in the management of individual cardiovascular diseases.     Integrates fundamentals and recent advances regarding cardiovascular drugs, blending basic and clinical sciences needed to effectively understand and treat cardiovascular diseases     Facilitates understanding of drug action and mechanism by covering physiology / pathophysiology and pharmacology     Includes guidelines and algorithms for pharmacotherapeutic management of cardiovascular diseases     Uses case presentations and study questions to enhance understanding of the material     Serves as a resource for pharmaceutical and medical students and researchers interested in cardiovascular issues.
Item type Current location Call number Status Date due Barcode Item holds
Ebrary Ebrary Afghanistan
Available EBKAF-N0001536
Ebrary Ebrary Algeria
Available
Ebrary Ebrary Cyprus
Available
Ebrary Ebrary Egypt
Available
Ebrary Ebrary Libya
Available
Ebrary Ebrary Morocco
Available
Ebrary Ebrary Nepal
Available EBKNP-N0001536
Ebrary Ebrary Sudan

Access a wide range of magazines and books using Pressreader and Ebook central.

Enjoy your reading, British Council Sudan.

Available
Ebrary Ebrary Tunisia
Available
Total holds: 0

Intro -- Title Page -- Copyright Page -- Contents -- Preface -- List of Abbreviations -- Unit I General Introduction -- Chapter 1 Introduction to Cardiovascular Diseases -- 1.1 Overview -- 1.2 Definition of Cardiovascular Diseases -- 1.3 Classification of Cardiovascular Diseases -- 1.3.1 Classification Based on Anatomical Location -- 1.3.2 Classification Based on the Involvement of Atherosclerosis -- 1.3.3 Total Cardiovascular Diseases and ICD-10 Classification -- 1.4 Prevalence, Incidence, and Trend of Cardiovascular Diseases -- 1.4.1 NCDs and Cardiovascular Diseases: The Global Status -- 1.4.2 The Status of Cardiovascular Diseases in the United States -- 1.4.3 The Status of Cardiovascular Diseases in China -- 1.5 Risk Factors of Cardiovascular Diseases -- 1.5.1 Classification of Cardiovascular Disease Risk Factors -- 1.5.2 Major Cardiovascular Disease Risk Factors and Their Impact -- 1.6 Prevention and Control of Cardiovascular Diseases -- 1.6.1 The UN High-Level Meeting and Tackling Cardiovascular Diseases at the Global Level -- 1.6.2 The World Heart Federation Call to Action to Prevent and Control Cardiovascular Diseases -- 1.6.3 The AHA 2010 Health Impact Goal, 2020 Health Impact Goal, and Ideal Cardiovascular Health -- 1.6.4 US DHSS "Million Hearts" Initiative -- 1.7 Cardiovascular Risk Prediction and Evidence-based Treatments -- 1.7.1 Cardiovascular Risk Prediction -- 1.7.2 Evidence-Based Treatments -- 1.8 Summary of Chapter Key Points -- 1.9 Self-Assessment Questions -- References -- Chapter 2 Introduction to Principles of Pharmacology -- 2.1 Overview -- 2.2 Definitions and History -- 2.2.1 What Is Pharmacology? -- 2.2.2 Definitions of Related Terms -- 2.2.3 A Brief History of Pharmacology -- 2.3 Pharmacological Paradigm: the Central Dogma in Pharmacology -- 2.3.1 Drug Names, Sources, Preparations, and Administration.

2.3.2 Pharmacokinetics -- 2.3.3 Pharmacodynamics -- 2.3.4 Drug Toxicity -- 2.3.5 Pharmacogenetics and Pharmacogenomics -- 2.4 Principles of Drug Discovery, Development, and Regulation -- 2.4.1 Definitions -- 2.4.2 The Paradigm of Drug Creation and Survival -- 2.4.3 The FDA Drug Review and Approval Process -- 2.5 Pharmacology Subspecialties -- 2.6 Introduction to Cardiovascular Pharmacology -- 2.6.1 Definition and Scope -- 2.6.2 New Developments and Challenges -- 2.6.3 Systems Pharmacology in the Management of Cardiovascular Diseases -- 2.6.4 Polypill for the Management of Cardiovascular Diseases -- 2.6.5 Protein Therapeutics of Cardiovascular Diseases -- 2.6.6 Gene Therapy of Cardiovascular Diseases -- 2.6.7 Stem Cell Therapy of Cardiovascular Diseases -- 2.7 Summary of Chapter Key Points -- 2.8 Self-Assessment Questions -- References -- Unit II Dyslipidemias -- Chapter 3 Overview of Dyslipidemias and Drug Therapy -- 3.1 Introduction -- 3.2 Lipoprotein Metabolism -- 3.2.1 Definition, Structure, and Classification of Lipoproteins -- 3.2.2 Metabolic Pathways of Lipoproteins and Drug Therapy -- 3.3 Dyslipidemias and Genetic Lipoprotein Disorders -- 3.3.1 Classification and Molecular Etiologies -- 3.3.2 The Four Types of Dyslipidemias and Their Underlying Genetic Lipoprotein Disorders -- 3.4 Mechanistically Based Drug Therapy of Dyslipidemias -- 3.5 Summary of Chapter Key Points -- 3.6 Self-Assessment Questions -- References -- Chapter 4 Drugs for Dyslipidemias -- 4.1 Overview -- 4.2 Statins -- 4.2.1 General Introduction to Drug Class -- 4.2.2 Chemistry and Pharmacokinetics -- 4.2.3 Molecular Mechanisms and Pharmacological Effects -- 4.2.4 Clinical Uses -- 4.2.5 Therapeutic Dosages -- 4.2.6 Adverse Effects and Drug Interactions -- 4.2.7 Summary of Statin Drugs -- 4.3 Bile Acid Sequestrants -- 4.3.1 General Introduction to Drug Class.

4.3.2 Chemistry and Pharmacokinetics -- 4.3.3 Molecular Mechanisms and Pharmacological Effects -- 4.3.4 Clinical Uses -- 4.3.5 Therapeutic Dosages -- 4.3.6 Adverse Effects and Drug Interactions -- 4.3.7 Summary of Bile Acid Sequestrants -- 4.4 Cholesterol Absorption Inhibitors -- 4.4.1 General Introduction to Drug Class -- 4.4.2 Chemistry and Pharmacokinetics -- 4.4.3 Molecular Mechanisms and Pharmacological Effects -- 4.4.4 Clinical Uses -- 4.4.5 Therapeutic Dosages -- 4.4.6 Adverse Effects and Drug Interactions -- 4.4.7 Summary of Ezetimibe -- 4.5 Fibrates -- 4.5.1 General Introduction to Drug Class -- 4.5.2 Chemistry and Pharmacokinetics -- 4.5.3 Molecular Mechanisms and Pharmacological Effects -- 4.5.4 Clinical Uses -- 4.5.5 Therapeutic Dosages -- 4.5.6 Adverse Effects and Drug Interactions -- 4.5.7 Summary of Fibrates -- 4.6 Niacin -- 4.6.1 General Introduction to Niacin -- 4.6.2 Chemistry and Pharmacokinetics -- 4.6.3 Molecular Mechanisms and Pharmacological Effects -- 4.6.4 Clinical Uses -- 4.6.5 Therapeutic Dosages -- 4.6.6 Adverse Effects and Drug Interactions -- 4.6.7 Summary of Niacin -- 4.7 New Drugs for HoFH -- 4.7.1 Lomitapide -- 4.7.2 Mipomersen -- 4.7.3 Summary of New Drugs for HoFH -- 4.8 Phytosterols and Phytostanols -- 4.8.1 Introduction to Phytosterols and Phytostanols -- 4.8.2 Molecular Mechanisms and Pharmacological Effects -- 4.8.3 Clinical Uses -- 4.8.4 Therapeutic Dosages -- 4.8.5 Adverse Effects and Drug Interactions -- 4.8.6 Summary of Phytosterols/Phytostanols -- 4.9 Omega-3 Fatty Acids -- 4.9.1 Introduction to Omega-3 Fatty Acids -- 4.9.2 Molecular Mechanisms and Pharmacological Effects -- 4.9.3 Clinical Uses -- 4.9.4 Therapeutic Dosages -- 4.9.5 Adverse Effects and Drug Interactions -- 4.9.6 Summary of Omega-3 Fatty Acids -- 4.10 Emerging Therapeutic Modalities for Dyslipidemias.

4.10.1 Emerging Therapeutic Strategies Targeting LDL -- 4.10.2 Novel Therapeutic Strategies Targeting HDL -- 4.10.3 Summary of Emerging Drugs -- 4.11 Summary of Chapter Key Points -- 4.12 Self-Assessment Questions -- References -- Chapter 5 Management of Dyslipidemias: Principles and Guidelines -- 5.1 Overview -- 5.2 General Principles of the Management of Dyslipidemias -- 5.2.1 Defining Dyslipidemias in the Context of Disease Management -- 5.2.2 Understanding Laboratory Lipid Profiles -- 5.2.3 Cardiovascular Risk Assessment -- 5.2.4 Treatment Goals -- 5.2.5 General Approaches to Management: Lifestyle Modifications and Drug Therapies -- 5.2.6 Management in Specific Clinical Settings -- 5.2.7 Treatment Monitoring and Adherence -- 5.3 Current Evidence-Based Guidelines on the Management of Dyslipidemias -- 5.3.1 Defining Clinical Guidelines in the Context of Dyslipidemia Management -- 5.3.2 Classification of Evidence-Based Guideline Recommendations and Strength of Evidence -- 5.3.3 Current Guidelines on the Management of Dyslipidemias -- 5.3.4 Comparison and Contrast of Current Lipid Guidelines -- 5.4 Summary of Chapter Key Points -- 5.5 Self-Assessment Questions -- References -- Unit III Hypertension and Multitasking Cardiovascular Drugs -- Chapter 6 Overview of Hypertension and Drug Therapy -- 6.1 Introduction -- 6.2 Definitions, Classifications, and Epidemiology of Hypertension -- 6.2.1 Definitions and Classifications -- 6.2.2 Epidemiology and Health Impact of Hypertension -- 6.3 Pathophysiology of Hypertension -- 6.3.1 Physiology of Blood Pressure Regulation -- 6.3.2 Molecular Pathophysiology of Hypertension Development -- 6.4 Mechanistically Based Drug Therapy of Hypertension: An Overview -- 6.4.1 Historical Overview -- 6.4.2 Mechanistic Overview -- 6.5 Summary of Chapter Key Points -- 6.6 Self-Assessment Questions -- References.

Chapter 7 Diuretics -- 7.1 Overview -- 7.2 Volume Regulation and Drug Targeting -- 7.2.1 Renal Physiology and Volume Regulation -- 7.2.2 Drug Class and Drug Targeting -- 7.3 Thiazide and Thiazide-Type Diuretics -- 7.3.1 General Introduction to Drug Class -- 7.3.2 Chemistry and Pharmacokinetics -- 7.3.3 Molecular Mechanisms and Pharmacological Effects -- 7.3.4 Clinical Uses -- 7.3.5 Therapeutic Dosages in Cardiovascular Applications -- 7.3.6 Adverse Effects and Drug Interactions -- 7.3.7 Summary of Thiazide and Thiazide-Type Diuretics -- 7.4 Loop Diuretics -- 7.4.1 General Introduction to Drug Class -- 7.4.2 Chemistry and Pharmacokinetics -- 7.4.3 Molecular Mechanisms and Pharmacological Effects -- 7.4.4 Clinical Uses -- 7.4.5 Therapeutic Dosages in Heart Failure Treatment -- 7.4.6 Adverse Effects and Drug Interactions -- 7.4.7 Summary of Loop Diuretics -- 7.5 Potassium-Sparing Diuretics -- 7.5.1 General Introduction to Drug Class -- 7.5.2 Chemistry and Pharmacokinetics -- 7.5.3 Molecular Mechanisms and Pharmacological Effects -- 7.5.4 Clinical Uses -- 7.5.5 Therapeutic Dosages -- 7.5.6 Adverse Effects and Drug Interactions -- 7.6 Other Diuretics -- 7.7 Summary of Chapter Key Points -- 7.8 Self-Assessment Questions -- References -- Chapter 8 Sympatholytics -- 8.1 Overview -- 8.2 Sympathetic Nervous System and Drug Targeting -- 8.2.1 Basic Divisions of the Nervous System -- 8.2.2 Sympathetic Nervous System and Cardiovascular Diseases -- 8.2.3 Drug Class and Drug Targeting -- 8.3 α-Adrenergic Receptor Antagonists -- 8.4 β-Adrenergic Receptor Antagonists -- 8.4.1 General Introduction to Drug Class -- 8.4.2 Chemistry and Pharmacokinetics -- 8.4.3 Molecular Mechanisms and Pharmacological Effects -- 8.4.4 Clinical Uses -- 8.4.5 Dosage Forms and Strengths -- 8.4.6 Adverse Effects and Drug Interactions -- 8.5 Centrally Acting Sympatholytics.

8.6 Summary of Chapter Key Points.

Written in an accessible style and consistent format, the book covers both the fundamentals and advances in the pharmacology of cardiovascular drugs, as well as their integrated applications in the management of individual cardiovascular diseases.     Integrates fundamentals and recent advances regarding cardiovascular drugs, blending basic and clinical sciences needed to effectively understand and treat cardiovascular diseases     Facilitates understanding of drug action and mechanism by covering physiology / pathophysiology and pharmacology     Includes guidelines and algorithms for pharmacotherapeutic management of cardiovascular diseases     Uses case presentations and study questions to enhance understanding of the material     Serves as a resource for pharmaceutical and medical students and researchers interested in cardiovascular issues.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2019. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.

There are no comments for this item.

to post a comment.